青少年系统性红斑狼疮伴肾功能衰竭患者外周血T、B淋巴细胞Fas表达及凋亡的变化
摘要
目的探讨青少年系统性红斑狼疮伴肾功能衰竭患者外周血T、B淋巴细胞Fas表达及凋亡。方法选取50例青少年系统性红斑狼疮伴肾功能衰竭患者为研究对象,根据疾病活动程度将其分为活动期组(n=27)、稳定期组(n=23),选取同期入院体检的20例健康青少年为对照组(n=20),比较外周血T、B淋巴细胞Fas表达及细胞凋亡情况。结果对照组外周血T、B淋巴细胞Fas表达低于另外两组,活动期组高于稳定期组(P <0. 05); T、B淋巴细胞凋亡率从高到低为活动期组、稳定期组、对照组(P <0. 05)。对照组CD4~+、CD8~+、CD19~+、CD23~+Fas表达量低于活动期组及稳定期组,活动期组高于稳定期组(P <0. 05)。对照组CD4~+中bc1-2表达高于另外两组,稳定期组高于活动期组(P <0. 05);对照组CD8~+、CD19~+、CD23~+中bc1-2表达低于另外两组,稳定期组低于活动期组(P <0. 05)。结论青少年系统性红斑狼疮伴肾功能衰竭患者外周血T、B淋巴细胞异常凋亡与Fas表达上调有关。
引文
[1] Ali M,Firoz CK,Jabir NR,et al. An Insight on the Pathogenesis and Treatment of Systemic Lupus Erythematosus[J]. Endocr Metab Immune Disord Drug Targets,2018,18(2):110-123.DOI:10. 2174/1871530318666171207145003.
[2] Romo-Tena J,Rajme-López S,Aparicio-Vera L,et al. Lys63-polyubiquitination by the E3 ligase casitas B-lineage lymphoma-b(Cbl-b)modulates peripheral regulatory T cell tolerance in patients with systemic lupus erythematosus[J]. Clin Exp Immunol,2018,191(1):42-49. DOI:10. 1111/cei. 13054.
[3] Nakayama Y,Kosek J,Capone L,et al. Aiolos Overexpression in Systemic Lupus Erythematosus B Cell Subtypes and BAFF-Induced Memory B Cell Differentiation Are Reduced by CC-220 Modulation of Cereblon Activity[J]. J Immunol,2017,199(7):2388-2407.DOI:10. 4049/jimmunol. 1601725.
[4] Huang C,Zhang L,Ling F,et al. Effect of immune tolerance induced by immature dendritic cells and CTLA4-Ig on systemic lupus erythematosus:An in vivo study[J]. Exp Ther Med,2018,15(3):2499-2506. DOI:10. 3892/etm. 2018. 5697.
[5] Yu X,Zhang N,Lin W,et al. Regulatory effects of four ginsenoside monomers in humoral immunity of systemic lupus erythematosus[J]. Exp Ther Med,2018,15(2):2097-2103. DOI:10.3892/etm. 2017. 5657.
[6] Zhang CX,Cai L,Shao K,et al. Serum IP-10 is useful for identifying renal and overall disease activity in pediatric systemic lupus erythematosus[J]. Pediatr Nephrol,2018,33(5):837-845.DOI:10. 1007/s00467-017-3867-1.
[7] Liphaus BL,MHB K,Carrasco S,et al. Increased serum s Fas,s TRAIL,and reduced s Fas L in juvenile-onset systemic lupus erythematosus[J]. Clin Rheumatol,2017,36(12):2847-2852.DOI:10. 1007/s10067-017-3615-8.
[8] Li M,Yu D,Ni B,et al. Interleukin-1 receptor associated kinase1 is a potential therapeutic target of anti-inflammatory therapy for systemic lupus erythematosus[J]. Mol Immunol,2017,87:94-101. DOI:10. 1016/j. molimm. 2017. 03. 018.
[9] Glesse N,Vianna P,LMG P,et al. Evaluation of polymorphic variants in apoptotic genes and their role in susceptibility and clinical progression to systemic lupus erythematosus[J]. Lupus,2017,26(7):746-755. DOI:10. 1177/0961203316678671.
[10]蔡皓月,蔡志海,邵丽萍.白芍总苷在系统性红斑狼疮治疗中的疗效分析[J].中国医师杂志,2017,19(3):445-447.DOI:10. 3760/cma. j. issn. 1008-1372. 2017. 03. 036.
[2] Romo-Tena J,Rajme-López S,Aparicio-Vera L,et al. Lys63-polyubiquitination by the E3 ligase casitas B-lineage lymphoma-b(Cbl-b)modulates peripheral regulatory T cell tolerance in patients with systemic lupus erythematosus[J]. Clin Exp Immunol,2018,191(1):42-49. DOI:10. 1111/cei. 13054.
[3] Nakayama Y,Kosek J,Capone L,et al. Aiolos Overexpression in Systemic Lupus Erythematosus B Cell Subtypes and BAFF-Induced Memory B Cell Differentiation Are Reduced by CC-220 Modulation of Cereblon Activity[J]. J Immunol,2017,199(7):2388-2407.DOI:10. 4049/jimmunol. 1601725.
[4] Huang C,Zhang L,Ling F,et al. Effect of immune tolerance induced by immature dendritic cells and CTLA4-Ig on systemic lupus erythematosus:An in vivo study[J]. Exp Ther Med,2018,15(3):2499-2506. DOI:10. 3892/etm. 2018. 5697.
[5] Yu X,Zhang N,Lin W,et al. Regulatory effects of four ginsenoside monomers in humoral immunity of systemic lupus erythematosus[J]. Exp Ther Med,2018,15(2):2097-2103. DOI:10.3892/etm. 2017. 5657.
[6] Zhang CX,Cai L,Shao K,et al. Serum IP-10 is useful for identifying renal and overall disease activity in pediatric systemic lupus erythematosus[J]. Pediatr Nephrol,2018,33(5):837-845.DOI:10. 1007/s00467-017-3867-1.
[7] Liphaus BL,MHB K,Carrasco S,et al. Increased serum s Fas,s TRAIL,and reduced s Fas L in juvenile-onset systemic lupus erythematosus[J]. Clin Rheumatol,2017,36(12):2847-2852.DOI:10. 1007/s10067-017-3615-8.
[8] Li M,Yu D,Ni B,et al. Interleukin-1 receptor associated kinase1 is a potential therapeutic target of anti-inflammatory therapy for systemic lupus erythematosus[J]. Mol Immunol,2017,87:94-101. DOI:10. 1016/j. molimm. 2017. 03. 018.
[9] Glesse N,Vianna P,LMG P,et al. Evaluation of polymorphic variants in apoptotic genes and their role in susceptibility and clinical progression to systemic lupus erythematosus[J]. Lupus,2017,26(7):746-755. DOI:10. 1177/0961203316678671.
[10]蔡皓月,蔡志海,邵丽萍.白芍总苷在系统性红斑狼疮治疗中的疗效分析[J].中国医师杂志,2017,19(3):445-447.DOI:10. 3760/cma. j. issn. 1008-1372. 2017. 03. 036.